Ulcerative Colitis

Join Clinical Trials for Ulcerative Colitis

Join Clinical Trials for Ulcerative Colitis

General purpose: Individuals with ulcerative colitis have immune system abnormalities, but it is not known if those abnormalities are a cause or a result of the ulcerative colitis.

Therefore, research may seek to uncover the relationship between immune system abnormalities and the development of ulcerative colitis.

Ulcerative Colitis Clinical Trials Continued … (Click to Open)

Join Clinical Trials for Ulcerative Colitis

Ulcerative Colitis Clinical Trials

Other studies may also evaluate the role that normal intestinal bacteria have in the development of the conditions. Other studies may look more closely at demographic factors, such as why ulcerative colitis tends to develop at a young age (usually between ages 15 and 30), rather than in later years (age 60 and over)l.

What do clinical trials for Ulcerative Colitis involve?

Clinical trials will vary widely in the information they collect, as well as the tests and procedures they use. All of these factors will depend on individual study designs, which will differ greatly between trials.

However, below is a list of common procedures and data that are frequently collected during a trial for ulcerative colitis:

  • Blood tests to measure
    • levels of certain immune system markers or genetic factors
    • how new drugs work in the body to treat ulcerative colitis
    • complete blood count
    • ESR / sed rate
    • C-reactive protein
  • Biopsies of areas of intestinal inflammation
  • Stool samples
  • Urine samples
  • Blood tests to determine
  • Barium enema
  • Colonoscopy with biopsy

Examples of ulcerative colitis- related research topics:

  • Studies looking at the immune system abnormalities of individuals with ulcerative colitis in order to understand how and why it develops.
  • Studies of new and affordable drugs to treat active ulcerative colitis.
  • Studies of genetic alterations that may predispose individuals, particularly children, to developing ulcerative colitis.
  • Studies investigating the difference in the prognosis of ulcerative colitis between current smokers and former smokers.
  • Studies assessing the quality of life, emotional status, and social interaction of individuals with ulcerative colitis.
  • Studies investigating the risk of colon cancer among individuals with ulcerative colitis.

Suggested search terms for best results: 

“Ulcerative Colitis“ “ulcerative colitis children,” “ulcerative colitis treatment,” “ulcerative colitis cancer,” “ulcerative colitis surgery,” and “ulcerative colitis remission.”



Study Evaluating the Long-term Safety and Efficacy of ABX464 in Active Ulcerative Colitis


Condition:   Ulcerative Colitis
Intervention:   Drug: ABX464
Sponsors:   Abivax S.A.;   Orion Corporation, Orion Pharma
Recruiting


Phase 2 Dose-finding IMU-838 for Ulcerative Colitis


Condition:   Ulcerative Colitis
Interventions:   Drug: IMU-838;   Drug: Placebo
Sponsor:   Immunic AG
Not yet recruiting


Efficacy and Safety of AbGn-168H in Patients With Moderate to Severe Active, Anti-TNF Alpha and/or Anti-integrin Refractory Ulcerative Colitis


Condition:   Ulcerative Colitis
Intervention:   Biological: AbGn-168H
Sponsor:   AbGenomics International, Inc.
Not yet recruiting


Study of the Effect of SHP647 as Maintenance Treatment in Participants With Moderate to Severe Ulcerative Colitis Who Achieved Clinical Response in Induction Studies


Condition:   Ulcerative Colitis
Interventions:   Drug: SHP647;   Other: Placebo
Sponsor:   Shire
Not yet recruiting


A Phase 3 Long-term Safety Extension Study of SHP647 in Subjects With Moderate to Severe Ulcerative Colitis (AIDA)


Condition:   Ulcerative Colitis
Interventions:   Drug: 25 mg SHP647;   Drug: 75 mg SHP647
Sponsor:   Shire
Not yet recruiting


A Study of Tofacitinib in Patients With Ulcerative Colitis in Stable Remission


Condition:   Ulcerative Colitis
Interventions:   Drug: CP-690,500 5 mg;   Drug: CP-690,550 10 mg
Sponsor:   Pfizer
Recruiting


Faecal Bacteriotherapy for Ulcerative Colitis


Condition:   Ulcerative Colitis
Interventions:   Other: Faecal bacterial transplantation;   Drug: Mesalazine 4G Enema
Sponsors:   Institute for Clinical and Experimental Medicine;   Institute of Animal Physiology and Genetics Academy of Science Czech Republic
Recruiting


ABX464 in Subjects With Moderate to Severe Active Ulcerative Colitis


Condition:   Ulcerative Colitis
Interventions:   Drug: ABX464;   Drug: Placebo oral capsule
Sponsor:   Abivax S.A.
Recruiting


Optimal Fecal Microbiota Transplant Dosing for Mild to Moderate Ulcerative Colitis


Condition:   Ulcerative Colitis
Interventions:   Biological: Fecal Microbiota Transplantation (FMT), OpenBiome;   Other: pretreatment antibiotics
Sponsor:   Najwa Elnachef
Recruiting


Safety and Efficacy Study of PTG-100 in the Treatment of Moderate to Severe Ulcerative Colitis


Condition:   Ulcerative Colitis
Interventions:   Drug: PTG-100;   Drug: Placebo group
Sponsor:   Protagonist Therapeutics
Recruiting


Development of a Biomarker of Efficacy of Vedolizumab (EnTyvio®) in Patients With ulcErative ColiTis (DETECT)


Condition:   ULCERATIVE COLITIS
Interventions:   Drug: VEDOLIZUMAB;   Drug: ADALIMUMAB
Sponsors:   Nantes University Hospital;   Takeda;   Mauna Kea Technologies;   Institut national de la santé et de la recherche médicale unité U1235 FRANCE;   Institut national de la santé et de la recherche médicale unité1064 FRANCE
Recruiting


Ulcerative Colitis Relapse Prevention by Prebiotics


Condition:   Ulcerative Colitis
Interventions:   Dietary Supplement: Synergy-1;   Dietary Supplement: Maltodextrin
Sponsors:   University of Alberta;   University of British Columbia
Recruiting


Long-term Safety and Efficacy Study of Adalimumab in Pediatric Subjects With Ulcerative Colitis


Condition:   Ulcerative Colitis
Intervention:   Biological: Adalimumab
Sponsor:   AbbVie
Enrolling by invitation


Safety and Efficacy of QBECO in Moderate to Severe Ulcerative Colitis


Condition:   Ulcerative Colitis
Intervention:   Biological: QBECO SSI
Sponsor:   Qu Biologics Inc.
Completed


Efficacy and Safety Study of Apremilast to Treat Active Ulcerative Colitis


Condition:   Ulcerative Colitis
Interventions:   Drug: Apremilast;   Drug: Placebo
Sponsor:   Celgene
Active, not recruiting


Study to Evaluate the Safety and Efficacy of Two Drug Regimens in Subjects With Moderate to Severe Ulcerative Colitis


Condition:   Ulcerative Colitis
Interventions:   Drug: Adalimumab;   Other: Placebo
Sponsor:   AbbVie
Recruiting


Efficacy and Safety of Adalimumab in Pediatric Subjects With Moderate to Severe Ulcerative Colitis


Condition:   Ulcerative Colitis
Interventions:   Biological: Adalimumab;   Other: Placebo
Sponsor:   AbbVie
Recruiting


FMT in Ulcerative Colitis-Associated Pouchitis


Condition:   Ulcerative Colitis Associated Pouchitis
Interventions:   Biological: biologically active human fecal microbiota;   Procedure: sigmoidoscopy
Sponsor:   Virginia O. Shaffer
Active, not recruiting


Special Investigation in Patients With Ulcerative Colitis


Condition:   Ulcerative Colitis
Intervention:  
Sponsor:   AbbVie
Active, not recruiting


Long-Term Safety Of PF-00547659 In Ulcerative Colitis


Condition:   Ulcerative Colitis
Interventions:   Drug: 75mg PF-00547659;   Drug: 225mg PF-00547659
Sponsor:   Shire
Completed


Pharmacokinetics of Adalimumab With Methotrexate for Treatment of Patients With Ulcerative Colitis (UC)


Condition:   Ulcerative Colitis
Interventions:   Drug: MTX 12.5;   Drug: MTX 25;   Drug: Adalimumab
Sponsors:   University of Western Ontario, Canada;   Abbott
Active, not recruiting


AMG 181 Phase 2 Study in Subjects With Moderate to Severe Ulcerative Colitis


Condition:   Ulcerative Colitis
Interventions:   Biological: AMG 181;   Other: Placebo
Sponsor:   Amgen
Active, not recruiting


Oral OKT3 for the Treatment of Active Ulcerative Colitis


Condition:   Ulcerative Colitis
Interventions:   Drug: Oral OKT3;   Drug: Omeprazole
Sponsor:   Brigham and Women's Hospital
Completed


Lactobacillus GG in Pediatric Ulcerative Colitis (UC)


Condition:   Ulcerative Colitis
Intervention:   Biological: Lactobacillus GG
Sponsor:   Children's Hospital Medical Center, Cincinnati
Withdrawn


Long-term Open-label Safety and Efficacy Study of Adalimumab in Subjects With Ulcerative Colitis


Condition:   Ulcerative Colitis
Intervention:   Biological: adalimumab
Sponsor:   AbbVie (prior sponsor, Abbott)
Completed

Refine Your Search Advanced Search